Immunology Weekly News – August 6th 2025

🧬 Immunology Updates: Breakthroughs in rheumatoid arthritis, chronic hepatitis B, ulcerative colitis, Crohn’s disease, alopecia areata, and more!

 

From FDA approvals to strategic partnerships and late-stage trial wins, these developments are redefining how we diagnose, treat, and manage autoimmune and inflammatory diseases. Let’s dive into the most impactful stories shaping immunology this week.

Here’s what you need to know ⬇️

🧠 FDA approves neuroimmune modulation device for rheumatoid arthritis — The SetPoint System, targeting the vagus nerve, achieved a 35.2 percent ACR20 response at 12 weeks in Phase 3 trials, offering a novel, minimally invasive therapy lasting up to 10 years.

🩺 MAGENTIQ EYE secures Series A funding — Boosting commercialization of its FDA- and CE-approved AI software for gastroenterology diagnostics, with ongoing trials in ulcerative colitis, Barrett’s esophagus, and gastric intestinal metaplasia.

🧬 HKUMed launches global gene therapy trial for chronic hepatitis B — One of only three sites worldwide, aiming to silence or remove viral genetic material without altering the human genome, potentially eliminating lifelong antiviral use.

🌍 Polpharma Biologics & Fresenius Kabi sign biosimilar licensing deal — PB016, a biosimilar to Entyvio®, targets moderate-to-severe ulcerative colitis and Crohn’s disease, with global rights excluding the MENA region.

❌ AbbVie ends IL-1 asset as monotherapy in ulcerative colitis — Following Phase 2 results showing insufficient efficacy, the company pivots to Crohn’s disease combination trials with Skyrizi.

🦠 Microbiotica completes Phase 1b recruitment — MB310, an oral microbiome therapy for mild-to-moderate ulcerative colitis, could induce remission without immunosuppression; results expected by year-end.

🤝 Dr Falk Pharma partners with Allianthera — Developing ATB102, an AhR agonist for refractory moderate-to-severe ulcerative colitis, with plans for a novel colonic-release formulation.

💉 Jeuveau named top neurotoxin performer — Independent JAMA Dermatology study found fastest onset, strongest peak, and longest duration versus Botox, Dysport, and Xeomin; now holds over 14 percent of the US market.

💇 Upadacitinib shines in alopecia areata Phase 3 trials — Up to 54.3 percent of patients achieved at least 80 percent scalp hair coverage at 24 weeks, with improvements in eyebrows and eyelashes.

📢 Stay Ahead in Immunology Research!

✅ Like, share, and subscribe for weekly updates on immunology and autoimmune diseases

#Immunology #AutoimmuneDiseases #RheumatoidArthritis #UlcerativeColitis #CrohnsDisease #AlopeciaAreata #ChronicHepatitisB #LucidQuest #ClinicalTrials #FDAupdates #MedicalNews #HealthcareInnovation